CareDx (CDNA) Earnings Expected to Grow: Should You Buy?
CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CDNA - CareDx, Inc
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$40.00
DETAILS
HIGH:
$45.00
LOW:
$35.00
MEDIAN:
$40.00
CONSENSUS:
$40.00
UPSIDE:
9.56%
Stock News
Amova Asset Management Americas Inc. Increases Position in CareDx, Inc. $CDNA
Amova Asset Management Americas Inc. raised its holdings in shares of CareDx, Inc. (NASDAQ: CDNA) by 2.0% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,475,126 shares of the company's stock after purchasing an additional 28,510 shares during the period. Amova Asset
CareDx's Growth Prospects With Naveris Keep Me Bullish
CareDx has a transplant-testing franchise that taps into recurring surveillance demand and has deeper integration into transplant centers. I also think CDNA's AlloHeme gives them longer-term optionality in post-cell-therapy monitoring. More recently, CDNA sold Lab Products and purchased Naveris. These major strategic M&A deals mean CDNA now has a potential growth engine in oncology.
CareDx (CDNA) Moves 35.6% Higher: Will This Strength Last?
CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the conference call can be accessed on the Events & Presentations section of Car.
CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the finalization of the Medicare Local Coverage Determination (LCD) process related to molecular testing for solid organ allograft rejection. The final policy affirms coverage across CareDx's transplant surveillance offerings in kidney, heart, and lung. Kidney: The policy affirms coverage of AlloSure® Kidney for sur.
CareDx Completes Naveris Acquisition and Expands Oncology Reach
CDNA closes its Naveris buyout, adding NavDx and expanding its precision diagnostics reach into high-growth specialty oncology.
CareDx: The Transplant Platform Is Becoming A Specialty Diagnostics Compounder
CareDx has transformed into a focused, high-acuity specialty diagnostics platform, emphasizing repeat testing, data-rich services, and workflow integration. Recent strategic actions—Lab Products divestiture, Naveris acquisition, and VANTx launch—sharpen CDNA's growth profile, recurring revenue, and margin potential. Q1 2026 marked a shift to operating leverage: 39% revenue growth, gross margin expansion to 71%, and positive net income, with strong guidance for 2026.
CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy today announced the successful completion of its previously announced acquisition of Naveris, following the satisfaction of all closing conditions. The transaction terms were disclosed at the time of announcement in April 2026. Naveris's lead product, NavDx, is a blood-based test that detects and monitors viral-mediated cancers — in.
CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the closing of the previously announced sale of its Lab Products business to Eurobio Scientific. The transaction closed on June 30, 2026 following receipt of required Swedish regulatory clearan.
CareDx's CEO Sells 17K Shares
The CEO sold 17,683 shares for a transaction value of approximately ~$425,000 at a weighted average of around $24.03 per share on June 15. The transaction represented 2.7% of John Hanna's direct holdings.
CareDx (CDNA) Moves 11.5% Higher: Will This Strength Last?
CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
CareDx Precision Medicine Diagnostics Showcased in Over 30 Abstracts and 9 Oral Presentations at the 2026 American Transplant Congress
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced its participation at the American Transplant Congress (ATC) 2026, taking place June 20–24 in Boston, Massachusetts. Real-world clinical use and scientific advancements involving AlloSure® Kidne.
CareDx Inc (CDNA) Shares Fall 3.4% -- GF Value Says Still Overvalued
On June 16, 2026, CareDx Inc (CDNA) shares fell by 3.4% to a current price of $23.22. The stock has experienced a 52-week range with a high of $24.85 and a low
CareDx Announces Second KOAR Analysis Published in the Journal of the American Society of Nephrology
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the publication of a new analysis from the Kidney Allograft Outcomes AlloSure Registry (KOAR), a landmark multi-center study, in the Journal of the American Society of Nephrology (JASN). The se.
CareDx Sharpens Precision Diagnostics Push With Naveris Deal, AlloHeme Plans
CareDx NASDAQ: CDNA executives outlined the company's strategy to focus on precision diagnostics, expand into minimal residual disease testing and improve profitability during a Goldman Sachs-hosted discussion.
CareDx, Inc. (CDNA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
CareDx, Inc. (CDNA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Baron Discovery Fund Q1 2026: Who Moved The Needle
In the first quarter of 2026, Baron Discovery Fund declined 10.65% (Institutional Shares), trailing the Russell 2000 Growth Index by 7.84% due to significant underperformance in the software sector. Advanced Energy Industries, Inc.'s stock rose during the quarter as the market began to appreciate the strength that the company would see in both its data center and semiconductor end markets. Baron Discovery Fund sold its investment in Intapp, Inc. in the quarter as the team believes that its other software holdings have better overall competitive advantages.
CareDx Highlights 39% Q1 Growth, Naveris Oncology Push at Jefferies
CareDx NASDAQ: CDNA executives outlined the company's growth strategy, first-quarter performance and pipeline priorities during a presentation at the Jefferies Healthcare Conference, emphasizing transplant diagnostics, specialty oncology and digital workflow integration.
CareDx to Participate in Upcoming Investor Conferences
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the company will participate in the following investor conferences: Jefferies 2026 Global Healthcare Conference at the Marriot Marquis in New York, NY. Presentation on Wednesday, June 3, 2026,.
Price Targets
CareDx price target raised to $45 from $28 at BTIG
$45.00
(was $38.59)
BTIG
Craig-Hallum ups CareDx price target after 'quite favorable' Medicare LCD
$35.00
(was $36.91)
Craig-Hallum
CareDx price target raised to $28 from $26 at BTIG
$28.00
(was $21.91)
BTIG
CareDx, Inc (CDNA) PT Raised to $26 at BTIG
$26.00
(was $18.46)
Sung Ji Nam
·
BTIG
CareDx downgraded to Hold from Buy at Craig-Hallum
$26.00
(was $19.81)
Craig-Hallum
CareDx price target raised to $18 from $14 at Wells Fargo
$18.00
(was $20.57)
Brandon Couillard
·
Wells Fargo
CareDx price target lowered to $25 from $26 at H.C. Wainwright
$25.00
(was $21.13)
H.C. Wainwright
CareDx, Inc (CDNA) PT Lowered to $35 at BTIG
$35.00
(was $22.90)
Sung Ji Nam
·
BTIG
CareDx upgraded to Buy from Neutral at BTIG
$40.00
(was $33.00)
Mark Massaro
·
BTIG
CareDx price target raised to $40 from $32 at Craig-Hallum
$40.00
(was $32.98)
Bill Bonello
·
Craig-Hallum
CareDx price target raised to $32 from $22 at Craig-Hallum
$32.00
(was $19.99)
Bill Bonello
·
Craig-Hallum
Stephens Reiterates Overweight Rating on CareDx, Inc (CDNA)
$15.00
(was $8.29)
Mason Carrico
·
Stephens
Goldman Sachs Maintains Buy on CareDx, Lowers Price Target to $29
$29.00
(was $16.26)
Goldman Sachs
Stephens & Co. Initiates Coverage On CareDx with Overweight Rating, Announces Price Target of $50
$50.00
(was $31.72)
Stephens